Motor Speech Disorders and Other Speech Sound Disorders in Adults

5554V - Parkinson’s Disease-Related Dysarthria; a Randomized Controlled Trial of LSVT LOUD®, Standard Speech-Language Pathology or Neither

ON-DEMAND

Format: Technical Research (Virtual)

Audience: Students, International Affiliates, Public/Consumers, Researchers, Related Professionals, Assistants, Early Career Professionals (under 5 years)

Keywords: Dysarthria, Parkinson's Disease, Randomised controlled trial, Quality of Life, Evidence base

Presenting Author(s)

Marian Brady

Glasgow Caledonian University

View Slides View Handouts

Author Only (Not Presenting)(s)

Smitaa Patel

Birmingham Clinical Trials Unit, University of Birmingham
Rebecca Woolley

Birmingham Clinical Trials Unit, University of Birmingham
Ryan Ottridge

Birmingham Clinical Trials Unit, University of Birmingham
Naveed Saeed

Birmingham Clinical Trials Unit, University of Birmingham
Sue Jowett

Health Economics Unit, University of Birmingham
Jane Futterer

Birmingham Clinical Trials Unit, University of Birmingham
Helen Nankervis

King’s College London
Zainab Abdali

Health Economics Unit, University of Birmingham
Carl Clarke

Sandwell and West Birmingham Hospitals NHS Trust
Catherine Sackley

King’s College London
Avril Nicoll

NMAHP Research Unit
Pui Au

Birmingham Clinical Trials Unit, University of Birmingham
Christina Smith

University College London
Gillian Beaton

Queen Elizabeth Hospital, NHS Greater Glasgow and Clyde
Caroline Rick

University of Nottingham
Christopher Burton

School of Allied and Public Health Professions, Canterbury Christ Church University
Natalie Ives

Birmingham Clinical Trials Unit, University of Birmingham
Patricia Masterson-Algar

Bangor University
Sylvia Dickson

Glasgow Caledonian University

We will briefly review the research evidence base relating to speech-language pathology (SLP) interventions for people with dysarthria related to Parkinson’s Disease which supported the development of our large (n=388), definitive, randomised controlled trial, PDCOMM. Our primary outcome compared the Voice Handicap Index self-rated scores of people that received LSVT LOUD, ‘Standard’ SLP or No SLP for voice or speech problems. We will also describe and compare the treatment the speech-language-pathologists reported they delivered to the participants in both intervention groups and reflect on the clinical and research implications of our findings.

Learning Objectives:

Describe the evidence base informing the development of the PDCOMM randomised controlled trial and the design and delivery of the definitive PDCOMM trial
Interpret the strength, limitations and quality of the findings emerging from the definitive PDCOMM trial
Integrate findings from the PDCOMM randomised controlled trial into clinical practice and the rigorous approach to trial design, delivery, and reporting to their own research practice